Does chromostatin influence catecholamine release or blood pressure in vivo?

Peptides. 1994 Jan;15(1):195-7. doi: 10.1016/0196-9781(94)90190-2.

Abstract

Although the structure of chromogranin A (CgA) is now known, its ultimate physiological role remains elusive. Recently, an interior fragment of CgA [CgA(124-143)], also called chromostatin, was reported to suppress catecholamine release from chromaffin cells in vitro. We therefore explored chromostatin's biological actions when administered in vivo to anesthetized rodents with normal (Wistar-Kyoto rats) or elevated blood pressure (spontaneously hypertensive rats). Neither mean arterial pressure nor plasma epinephrine concentrations were significantly altered following either chromostatin or vehicle administration. Plasma norepinephrine, on the other hand, tended to rise throughout all studies, with the rise reaching statistical significance only in the SHR subgroup receiving chromostatin. We conclude that, unlike its actions in vitro, chromostatin does not appear to suppress catecholamine release or modulate blood pressure in vivo.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Blood Pressure / drug effects*
  • Catecholamines / metabolism*
  • Chromogranin A
  • Chromogranins / pharmacology*
  • Hypertension / drug therapy
  • Hypertension / physiopathology*
  • Male
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY

Substances

  • Catecholamines
  • Chromogranin A
  • Chromogranins
  • Peptide Fragments
  • chromostatin